Biosensors Of Singapore Eyes Bigger Share In China, Japan Stent Sales
This article was originally published in PharmAsia News
Executive Summary
Singapore's Biosensors plans to beef up its sales effort for drug-eluting stents in China in the wake of Johnson & Johnson's announced departure from that sector of the device industry. Biosensors also expects to increase its earnings from Japan through a licensing agreement with Terumo. With the exit of J&J from the stent market, Biosensors expects to increase its nearly 30% share of the $1 billion Chinese market. The Singapore firm's tie with Terumo is expected to provide a 20% share of the Japan market estimated to be worth as much as $600 million. (Click here for more
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.